Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04343885 |
Title | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA) |
Acronym | UpFrontPSMA |
Recruitment | Active, not recruiting |
Gender | male |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Peter MacCallum Cancer Centre, Australia |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | AUS |